Tomorrow the Swiss BB Biotech will publish its past quarters figures. For this year the company from Schaffhausen could earn a total revenue around 0 million CHF. This is according to the average of the analysts' estimates. This is hugely lower than 2020's revenue of 741.78 million CHF.
The analysts expect for 2021 a net profit of 357 million CHF. The majority of the analysts expects for this year a profit per share of 6.35 CHF. The PE-ratio therefore is 12.76.
Based on the current number of shares BB Biotech 's market capitalization equals 4.49 billion CHF. The BB Biotech stock was the past 12 months quite volatile. Since last April the stock is even 37 percent higher. This year the stock price moved between 57 and 93 CHF.
At 10.54 the stock trades 1.17 percent higher at 81.05 CHF.
Analist.nl Nieuwsdienst: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.